Neupro Now Available for Parkinson's and Restless Leg Syndrome

UCB announced that Neupro (rotigotine transdermal system) is now available as a once-daily patch for the treatment of signs and symptoms of early and advanced stage idiopathic Parkinson's disease (PD) and moderate-to-severe primary restless legs syndrome (RLS).

Rotigotine is a non-ergoline dopamine agonist that improves motor function and activities by stimulating the dopamine receptors within the caudate-putamen in the brain.

Neupro is available in four different dosage strengths (2mg/24 hours, 4mg/24 hours, 6mg/24 hours, and 8mg/24 hours) for the signs and symptoms of Parkinson's disease and in three different dosage strengths (1mg/24 hours, 2mg/24 hours, and 3mg/24 hours) for moderate-to-severe primary RLS.

For more information call (800) 477-7877 or visit www.neupro.com.